Biotage AB (publ) (BIOT.ST)
SEK 141.1
(0.21%)
SEK 141.1
(0.21%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 432 Million SEK | 2.37% |
| 2022 | 431 Million SEK | 25.22% |
| 2021 | 323 Million SEK | 22.38% |
| 2020 | 278.1 Million SEK | -4.79% |
| 2019 | 265.98 Million SEK | 33.01% |
| 2018 | 199.48 Million SEK | 59.57% |
| 2017 | 169.4 Million SEK | 0.0% |
| 2016 | 135.1 Million SEK | 16.68% |
| 2015 | 117.14 Million SEK | 54.56% |
| 2014 | 75.56 Million SEK | 5.8% |
| 2013 | 68.37 Million SEK | 6.3% |
| 2012 | 67.14 Million SEK | 138.35% |
| 2011 | 64.17 Million SEK | -94.46% |
| 2010 | 509.19 Million SEK | 1681.89% |
| 2009 | 28.57 Million SEK | -33.14% |
| 2008 | 63.83 Million SEK | -48.06% |
| 2007 | 82.28 Million SEK | 61.42% |
| 2006 | 50.98 Million SEK | 191.8% |
| 2005 | -55.53 Million SEK | 50.36% |
| 2004 | -111.86 Million SEK | 26.21% |
| 2003 | -194.04 Million SEK | -88.38% |
| 2002 | -80.47 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 111 Million SEK | -14.62% |
| 2024 Q2 | 130 Million SEK | 7.44% |
| 2024 Q1 | 121 Million SEK | -39.5% |
| 2023 Q1 | 80 Million SEK | -16.67% |
| 2023 FY | - SEK | 24.41% |
| 2023 Q3 | 114 Million SEK | 39.02% |
| 2023 Q2 | 82 Million SEK | 2.5% |
| 2023 Q4 | 195 Million SEK | 71.05% |
| 2022 Q3 | 122 Million SEK | 2.52% |
| 2022 FY | - SEK | 25.22% |
| 2022 Q1 | 119 Million SEK | 43.37% |
| 2022 Q2 | 119 Million SEK | 0.0% |
| 2022 Q4 | 96 Million SEK | -21.31% |
| 2021 FY | - SEK | 22.38% |
| 2021 Q1 | 96.51 Million SEK | 0.57% |
| 2021 Q2 | 81.03 Million SEK | -16.03% |
| 2021 Q4 | 83 Million SEK | -3.49% |
| 2021 Q3 | 86 Million SEK | 6.12% |
| 2020 Q1 | 80.3 Million SEK | 23.8% |
| 2020 FY | - SEK | -4.79% |
| 2020 Q4 | 95.96 Million SEK | 21.97% |
| 2020 Q3 | 78.67 Million SEK | 74.74% |
| 2020 Q2 | 45.02 Million SEK | -43.94% |
| 2019 FY | - SEK | 33.01% |
| 2019 Q3 | 83.41 Million SEK | 12.56% |
| 2019 Q2 | 74.1 Million SEK | 10.86% |
| 2019 Q1 | 66.84 Million SEK | 28.74% |
| 2019 Q4 | 64.86 Million SEK | -22.23% |
| 2018 Q1 | 50.76 Million SEK | 45.6% |
| 2018 FY | - SEK | 59.57% |
| 2018 Q2 | 59.91 Million SEK | 18.04% |
| 2018 Q3 | 54.83 Million SEK | -8.48% |
| 2018 Q4 | 51.91 Million SEK | -5.32% |
| 2017 Q3 | 29.25 Million SEK | -36.7% |
| 2017 Q1 | 43.21 Million SEK | 66.4% |
| 2017 Q2 | 46.22 Million SEK | 6.97% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q4 | 34.86 Million SEK | 19.16% |
| 2016 Q4 | 25.96 Million SEK | -33.45% |
| 2016 FY | - SEK | 16.68% |
| 2016 Q2 | 37.01 Million SEK | 8.03% |
| 2016 Q1 | 34.26 Million SEK | -1.73% |
| 2016 Q3 | 39.01 Million SEK | 5.42% |
| 2015 FY | - SEK | 54.56% |
| 2015 Q4 | 34.86 Million SEK | 25.23% |
| 2015 Q3 | 27.84 Million SEK | 4.19% |
| 2015 Q2 | 26.72 Million SEK | -3.29% |
| 2015 Q1 | 27.62 Million SEK | -6.36% |
| 2014 FY | - SEK | 5.8% |
| 2014 Q2 | 22.15 Million SEK | 29.48% |
| 2014 Q3 | 20.29 Million SEK | -8.41% |
| 2014 Q1 | 17.11 Million SEK | -30.59% |
| 2014 Q4 | 29.5 Million SEK | 45.42% |
| 2013 Q3 | 13.92 Million SEK | -29.56% |
| 2013 FY | - SEK | 6.3% |
| 2013 Q1 | 13.06 Million SEK | -35.56% |
| 2013 Q2 | 19.77 Million SEK | 51.34% |
| 2013 Q4 | 24.65 Million SEK | 76.99% |
| 2012 Q4 | 20.27 Million SEK | 14.63% |
| 2012 Q3 | 17.68 Million SEK | -3.24% |
| 2012 Q1 | 8.58 Million SEK | -53.93% |
| 2012 Q2 | 18.28 Million SEK | 112.87% |
| 2012 FY | - SEK | 138.35% |
| 2011 FY | - SEK | -94.46% |
| 2011 Q2 | 1.75 Million SEK | -32.46% |
| 2011 Q3 | 10.91 Million SEK | 521.58% |
| 2011 Q4 | 18.64 Million SEK | 70.79% |
| 2011 Q1 | 2.6 Million SEK | 100.6% |
| 2010 Q3 | 4.84 Million SEK | -36.56% |
| 2010 Q2 | 7.63 Million SEK | 64.75% |
| 2010 Q1 | 4.63 Million SEK | -33.19% |
| 2010 FY | - SEK | 1681.89% |
| 2010 Q4 | -434.84 Million SEK | -9080.63% |
| 2009 Q2 | 5.97 Million SEK | -71.03% |
| 2009 Q4 | 6.93 Million SEK | 243.15% |
| 2009 Q1 | 20.62 Million SEK | 0.0% |
| 2009 FY | - SEK | -33.14% |
| 2009 Q3 | 2.02 Million SEK | -66.16% |
| 2008 FY | - SEK | -48.06% |
| 2007 FY | - SEK | 61.42% |
| 2006 FY | - SEK | 191.8% |
| 2005 FY | - SEK | 50.36% |
| 2004 FY | - SEK | 26.21% |
| 2003 FY | - SEK | -88.38% |
| 2002 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AddLife AB (publ) | 1.54 Billion SEK | 72.057% |
| Bonesupport Holding AB (publ) | 28.93 Million SEK | -1392.898% |
| Doxa AB (publ) | 296 Million SEK | -45.946% |
| Elekta AB (publ) | 3.29 Billion SEK | 86.873% |
| iZafe Group AB (publ) | -15.61 Million SEK | 2866.216% |
| Ortivus AB (publ) | -14.92 Million SEK | 2994.278% |
| Ortivus AB (publ) | -14.92 Million SEK | 2994.278% |
| Q-linea AB (publ) | -210.98 Million SEK | 304.753% |
| S2Medical AB (publ) | -13.52 Million SEK | 3293.111% |
| Synsam AB (publ) | 1.71 Billion SEK | 74.752% |